ARTES joins fight against COVID-19 with VLP vaccine platforms

ARTES Biotechnology, a Germany-based biotechnology company specialising in process development for recombinant vaccines, has commenced the development of SARS-CoV-2 vaccine candidates on its Virus-Like Particle (VLP) based platform technologies METAVAX® and SplitCore.

METAVAX® VLP vaccine platform

METAVAX® is the biotech’s proprietary platform for vaccine development built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles (cVLPs) are introduced as antigen presentation carriers without the intervention of host lipid membrane structures.

The ARTES Biotechnology development strategy is optimised to present domains of the SARS-CoV-2 spike protein, with or without an antigen derived from the nucleocapsid protein of the virus, on the VLPs (METAVAX®) and cVLPs (SplitCore) surface.

Dr. Michael Piontek, Managing Director of ARTES says:

“The battle against the COVID-19 pandemic will require a lot of different innovative approaches. We are convinced that our technology platform can provide on short term an important contribution in this global combat. The compelling advantage of our technology is the cost-effective production of efficacious and safe vaccines in a platform already applied in mass vaccination programs.”

Virus-like particle (VLP) vaccine technology

Virus-like particles are highly organised protein structures that imitate the conformation of genuine native viruses without being infectious. They are composed of one or more structural proteins that are capable of self-assembling to resemble the structure of authentic viruses and to display foreign epitopes or complete antigens on their surface. Recombinant VLPs are superior to native viruses due to lack of a viral genome whilst still possessing the same potential to set off a strong immune response.

In September last year, ARTES together with the Australian Burnett Institute released data on the efficient development of malaria vaccine candidates using virus-like particles (eVLP) generated with the proprietary ARTES Biotechnology METAVAX® platform presenting malaria transmission-stage antigens, which were capable of triggering transmission-blocking antibodies.

A team of researchers from the University of Freiburg developed for the ARTES SplitCore platform, borrelia antigen presenting cVLP and resulted in the induction of neutralising antibodies against Lyme disease.

Applying a similar strategy, SARS-CoV-2 antigens known to evoke the neutralising antibodies will be presented by the METAVAX ® and SplitCore VLPs.

ARTES has special expertise in the vaccine process development from microbial expression systems with several licenced products released. The biotechnology company provides two versatile and tested virus-like particle (VLP) platform technologies for the development of vaccine candidates.

The generated virus-like particles from the bacterial and yeast cell lines are applicable in both human and animal health as highly immunogenic subunit vaccines.

More about ARTES Biotechnology

Since 2002, ARTES Biotechnology has positioned itself as a valued partner for the pharmaceutical industry with its cutting edge proprietary expression systems and its broad know-how and capabilities from cell line development to manufacturing.

Operating internationally, ARTES Biotechnology is a leader in the field of recombinant protein production. ARTES develops microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offers ready-to-transfer processes for a wide range of products. Operating internationally, ARTES Biotechnology is a leader in the field of recombinant protein production.

Original Source:

27 April 2020 – ARTES Biotechnology – Press Release: ARTES joins global combat against Corona